Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis.

Receptor activator of NF-κβ ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting pla...